Alexion’s Ultomiris Expands Its Reach As Soliris Biosimilars Loom
Executive Summary
The US firm’s Ultomiris reduced the risk of relapse in a late-stage trial for the serious autoimmune disease NMOSD, triggering plans for a label expansion to yet another indication currently dominated by its older product Soliris.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.